Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -4.99%) were lower by 4% as of 11 a.m. ET today. The move comes ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

Josh Lipton takes a closer look at some of the top stories of the trading day as part of Yahoo Finance's Market Minute.

Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

On behalf of an individual investor, Block & Leviton LLP filed a class action lawsuit today against Hims & Hers Health, Inc. (NYSE: HIMS), along with certain individuals, alleging that they violated ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) ...